Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLCAR.CD30 for CD30+ Nonseminomatous Germ Cell Tumors
NCT05634785Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATLCAR.CD30 T cells in non-seminomatous germ cell tumor (NSGCT), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Overall Response Rate (RECIST) at 6 weeks. Started Dec 2022; status: completed.
02
Drugs
ATLCAR.CD30 T cells
03
Conditions
non-seminomatous germ cell tumor (NSGCT)
Beyond the preview
Go deeper on NCT05634785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634785.